Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
This study has been completed.
Sponsor:
Kidney Cancer Research Bureau
Information provided by:
Kidney Cancer Research Bureau
ClinicalTrials.gov Identifier:
NCT01182142
First received: August 11, 2010
Last updated: August 22, 2010
Last verified: August 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed. In this trial, we are evaluating efficacy of capecitabine in metastatic renal cell carcinoma patients.
Condition | Intervention | Phase |
---|---|---|
Metastatic Renal Cell Carcinoma |
Drug: Capecitabine |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients |
Resource links provided by NLM:
Further study details as provided by Kidney Cancer Research Bureau:
Primary Outcome Measures:
- Overall response rate [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Overall survival Progression-free survival [ Time Frame: 24 months ] [ Designated as safety issue: No ]
Estimated Enrollment: | 51 |
Study Start Date: | September 2007 |
Study Completion Date: | August 2010 |
Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Capecitabine
All patients will receive capecitabine.
|
Drug: Capecitabine
1,250 mg/m2 orally twice a day, days 1-14
|
Eligibility
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- histologically confirmed non-clear cell renal cell carcinoma
- confirmed metastatic sites
- no chemotherapy in history
Exclusion Criteria:
- metastases in CNS
- previous targeted therapy
- other tumor
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01182142
Locations
Russian Federation | |
Natalia Petenko | |
Moscow, Russian Federation |
Sponsors and Collaborators
Kidney Cancer Research Bureau
Investigators
Principal Investigator: | Lev Demidov, MD, D.Sc. | N.N. Blokhin Russian Cancer Research Center |
More Information
Additional Information:
No publications provided by Kidney Cancer Research Bureau
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 17, 2012
Additional Information:
Related Info 
Related Info 
No publications provided by Kidney Cancer Research Bureau
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Lev Demidov, N.N. Blokhin Russian Cancer Research Center |
ClinicalTrials.gov Identifier: | NCT01182142 History of Changes |
Other Study ID Numbers: | CRT-06.CAP |
Study First Received: | August 11, 2010 |
Last Updated: | August 22, 2010 |
Health Authority: | Russia: Ministry of Health and Social Development of the Russian Federation |
Additional relevant MeSH terms:
Carcinoma Carcinoma, Renal Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases |
Capecitabine Fluorouracil Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents Therapeutic Uses Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on October 17, 2012